Diagnostic markers for glioblastoma

Histology and Histopathology

Volumn 26, Issue 10, 2011, Pages 1327-1341

  Jung, C S ^a   Unterberg, A W ^a   Hartmann, C ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Biomarker; Cerebrospinal fluid; Glioblastoma; Histopathology; Serum

Indexed keywords

TUMOR MARKER;

BRAIN TUMOR; GLIOBLASTOMA; HUMAN; METABOLISM; REVIEW;

BRAIN NEOPLASMS; GLIOBLASTOMA; HUMANS; TUMOR MARKERS, BIOLOGICAL;

EID: 80053327857     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (146)

1. Abaza M.S., Shaban F., Narayan R.K. and Atassi M.Z. (1998). Human glioma associated intermediate filament proteins: over-expression, co-localization and cross-reactivity. Anticancer Res. 18, 1333-1340.
2. Abraham C.R., Shirahama T. and Potter H. (1990). Alpha 1- antichymotrypsin is associated solely with amyloid deposits containing the beta-protein. Amyloid and cell localization of alpha 1-antichymotrypsin. Neurobiol. Aging 11, 123-129.
3. Alvord E.C. Jr (1992). Is necrosis helpful in the grading of gliomas? Editorial opinion. J. Neuropathol. Exp. Neurol. 51, 127-132.
4. Balss J., Meyer J., Mueller W., Korshunov A., Hartmann C. and von Deimling A. (2008). Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol. 116, 597-602.
5. Bao S., Wu Q., McLendon R.E., Hao Y., Shi Q., Hjelmeland A.B., Dewhirst M.W., Bigner D.D. and Rich J.N. (2006). Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444, 756-760.
6. Barker F.G. 2nd, Davis R.L., Chang S.M. and Prados M.D. (1996). Necrosis as a prognostic factor in glioblastoma multiforme. Cancer 77, 1161-1166.
7. Belanich M., Pastor M., Randall T., Guerra D., Kibitel J., Alas L., Li B., Citron M., Wasserman P., White A., Eyre H., Jaeckle K., Schulman S., Rector D., Prados M., Coons S., Shapiro W. and Yarosh D. (1996). Retrospective study of the correlation between the DNA repair protein alkyltransferase and survival of brain tumor patients treated with carmustine. Cancer Res. 56, 783-788.
8. Bleeker F.E., Lamba S., Leenstra S., Troost D., Hulsebos T., Vandertop W.P., Frattini M., Molinari F., Knowles M., Cerrato A., Rodolfo M., Scarpa A., Felicioni L., Buttitta F., Malatesta S., Marchetti A. and Bardelli A. (2009). IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors. Hum. Mutat. 30, 7-11.
9. Brandes A.A., Franceschi E., Tosoni A., Benevento F., Scopece L., Mazzocchi V., Bacci A., Agati R., Calbucci F. and Ermani M. (2009a). Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation status. Cancer 115, 3512-3518.
10. Brandes A.A., Tosoni A., Franceschi E., Sotti G., Frezza G., Amista P., Morandi L., Spagnolli F. and Ermani M. (2009b). Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: correlation With MGMT promoter methylation status. J. Clin. Oncol. 27, 1275-1279.
11. Brat D.J., Castellano-Sanchez A., Kaur B. and Van Meir E.G. (2002). Genetic and biologic progression in astrocytomas and their relation to angiogenic dysregulation. Adv. Anat. Pathol. 9, 24-36.
12. Brem S., Tsanaclis A.M., Gately S., Gross J.L. and Herblin W.F. (1992). Immunolocalization of basic fibroblast growth factor to the microvasculature of human brain tumors. Cancer 70, 2673-2680.
13. Brown P.D., Krishnan S., Sarkaria J.N., Wu W., Jaeckle K.A., Uhm J.H., Geoffroy F.J., Arusell R., Kitange G., Jenkins R.B., Kugler J.W., Morton R.F., Rowland K.M. Jr, Mischel P., Yong W.H., Scheithauer B.W., Schiff D., Giannini C. and Buckner J.C. (2008). Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177. J. Clin. Oncol. 26, 5603-5609.
14. Burger P.C. and Green S.B. (1987). Patient age, histologic features, and length of survival in patients with glioblastoma multiforme. Cancer 59, 1617-1625.
15. Burger P.C. and Vollmer R.T. (1980). Histologic factors of prognostic significance in the glioblastoma multiforme. Cancer 46, 1179-1186.
16. Burger P.C., Vogel F.S., Green S.B. and Strike T.A. (1985). Glioblastoma multiforme and anaplastic astrocytoma. Pathologic criteria and prognostic implications. Cancer 56, 1106-1111.
17. Burger P.C., Pearl D.K., Aldape K., Yates A.J., Scheithauer B.W., Passe S.M., Jenkins R.B. and James C.D. (2001). Small cell architecture-a histological equivalent of EGFR amplification in glioblastoma multiforme? J. Neuropathol. Exp. Neurol. 60, 1099-1104.
18. Capper D., Mittelbronn M., Meyermann R. and Schittenhelm J. (2008). Pitfalls in the assessment of MGMT expression and in its correlation with survival in diffuse astrocytomas: proposal of a feasible immunohistochemical approach. Acta Neuropathol. 115, 249-259.
19. Capper D., Zentgraf H., Balss J., Hartmann C. and von Deimling A. (2009). Monoclonal antibody specific for IDH1 R132H mutation. Acta Neuropathol. 118, 599-601.
20. Capper D., Weissert S., Balss J., Habel A., Meyer J., Jager D., Ackermann U., Tessmer C., Korshunov A., Zentgraf H., Hartmann C. and von Deimling A. (2010). Characterization of R132H mutationspecific IDH1 antibody binding in brain tumors. Brain Pathol. 20, 245-254.
21. CBTRUS (2010). CBTRUS Statistical Report: Primary Brain and Central Nervous Tumors Diagnosed in the United States in 2004-2006. Journal.
22. Cha S., Lupo J.M., Chen M.H., Lamborn K.R., McDermott M.W., Berger M.S., Nelson S.J. and Dillon W.P. (2007). Differentiation of glioblastoma multiforme and single brain metastasis by peak height and percentage of signal intensity recovery derived from dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Am. J. Neuroradiol. 28, 1078-1084.
23. Chinot O.L., Barrie M., Fuentes S., Eudes N., Lancelot S., Metellus P., Muracciole X., Braguer D., Ouafik L., Martin P.M., Dufour H. and Figarella-Branger D. (2007). Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide. J. Clin. Oncol. 25, 1470-1475.
24. Clarke J.L., Iwamoto F.M., Sul J., Panageas K., Lassman A.B., DeAngelis L.M., Hormigo A., Nolan C.P., Gavrilovic I., Karimi S. and Abrey L.E. (2009). Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma. J. Clin. Oncol. 27, 3861-3867.
25. Cochran A.J. and Wen D.R. (1985). S-100 protein as a marker for melanocytic and other tumours. Pathology 17, 340-345.
26. Coppola D., Szabo M., Boulware D., Muraca P., Alsarraj M., Chambers A.F. and Yeatman T.J. (2004). Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin. Cancer Res. 10, 184-190.
27. Criniere E., Kaloshi G., Laigle-Donadey F., Lejeune J., Auger N., Benouaich-Amiel A., Everhard S., Mokhtari K., Polivka M., Delattre J.Y., Hoang-Xuan K., Thillet J. and Sanson M. (2007). MGMT prognostic impact on glioblastoma is dependent on therapeutic modalities. J. Neurooncol. 83, 173-179.
28. Dang L., White D.W., Gross S., Bennett B.D., Bittinger M.A., Driggers E.M., Fantin V.R., Jang H.G., Jin S., Keenan M.C., Marks K.M., Prins R.M., Ward P.S., Yen K.E., Liau L.M., Rabinowitz J.D., Cantley L.C., Thompson C.B., Vander Heiden M.G. and Su S.M. (2009). Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462, 739-744.
29. Daumas-Duport C., Scheithauer B., O'Fallon J. and Kelly P. (1988). Grading of astrocytomas. A simple and reproducible method. Cancer 62, 2152-2165.
30. Dunn J., Baborie A., Alam F., Joyce K., Moxham M., Sibson R., Crooks D., Husband D., Shenoy A., Brodbelt A., Wong H., Liloglou T., Haylock B. and Walker C. (2009). Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy. Br. J. Cancer 101, 124-131.
31. Esteller M., Garcia-Foncillas J., Andion E., Goodman S.N., Hidalgo O.F., Vanaclocha V., Baylin S.B. and Herman J.G. (2000). Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N. Engl. J. Med. 343, 1350-1354.
32. Felsberg J., Rapp M., Loeser S., Fimmers R., Stummer W., Goeppert M., Steiger H.J., Friedensdorf B., Reifenberger G. and Sabel M.C. (2009). Prognostic significance of molecular markers and extent of resection in primary glioblastoma patients. Clin. Cancer Res. 15, 6683-6693.
33. Foerch C., Curdt I., Yan B., Dvorak F., Hermans M., Berkefeld J., Raabe A., Neumann-Haefelin T., Steinmetz H. and Sitzer M. (2006). Serum glial fibrillary acidic protein as a biomarker for intracerebral haemorrhage in patients with acute stroke. J. Neurol. Neurosurg. Psychiatry 77, 181-184.
34. Fritz A., Percy C., Jack A., Shanmugaratham K., Sobin L., Parkin M. and Whelan S. (2000). ICD-O International classification of diseases for oncology. World Health Organization. Geneva.
35. Fukuda M.E., Iwadate Y., Machida T., Hiwasa T., Nimura Y., Nagai Y., Takiguchi M., Tanzawa H., Yamaura A. and Seki N. (2005). Cathepsin D is a potential serum marker for poor prognosis in glioma patients. Cancer Res. 65, 5190-5194.
36. Fukui S., Nawashiro H., Otani N., Ooigawa H., Nomura N., Yano A., Miyazawa T., Ohnuki A., Tsuzuki N., Katoh H., Ishihara S. and Shima K. (2003). Nuclear accumulation of basic fibroblast growth factor in human astrocytic tumors. Cancer 97, 3061-3067.
37. Geisbrecht B.V. and Gould S.J. (1999). The human PICD gene encodes a cytoplasmic and peroxisomal NADP(+)-dependent isocitrate dehydrogenase. J. Biol. Chem. 274, 30527-30533.
38. Gerson S.L. (2004). MGMT: its role in cancer aetiology and cancer therapeutics. Nat. Rev. Cancer 4, 296-307.
39. Godard S., Getz G., Delorenzi M., Farmer P., Kobayashi H., Desbaillets I., Nozaki M., Diserens A.C., Hamou M.F., Dietrich P.Y., Regli L., Janzer R.C., Bucher P., Stupp R., de Tribolet N., Domany E. and Hegi M.E. (2003). Classification of human astrocytic gliomas on the basis of gene expression: a correlated group of genes with angiogenic activity emerges as a strong predictor of subtypes. Cancer Res. 63, 6613-6625.
40. Gorlia T., van den Bent M.J., Hegi M.E., Mirimanoff R.O., Weller M., Cairncross J.G., Eisenhauer E., Belanger K., Brandes A.A., Allgeier A., Lacombe D. and Stupp R. (2008). Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. Lancet Oncol. 9, 29-38.
41. Grasbon-Frodl E.M., Kreth F.W., Ruiter M., Schnell O., Bise K., Felsberg J., Reifenberger G., Tonn J.C. and Kretzschmar H.A. (2007). Intratumoral homogeneity of MGMT promoter hypermethylation as demonstrated in serial stereotactic specimens from anaplastic astrocytomas and glioblastomas. Int. J. Cancer 121, 2458-2464.
42. Griffin C.A., Burger P., Morsberger L., Yonescu R., Swierczynski S., Weingart J.D. and Murphy K.M. (2006). Identification of der(1;19)(q10;p10) in Five Oligodendrogliomas Suggests Mechanism of Concurrent 1p and 19q Loss. J. Neuropathol. Exp. Neurol. 65, 988-994.
43. Gronowitz J.S., Kallander C.F., Hagberg H. and Persson L. (1984). Deoxythymidine-kinase in cerebrospinal fluid: a new potential marker for brain tumours. Acta Neurochir. (Wien) 73, 1-12.
44. Gross S., Cairns R.A., Minden M.D., Driggers E.M., Bittinger M.A., Jang H.G., Sasaki M., Jin S., Schenkein D.P., Su S.M., Dang L., Fantin V.R. and Mak T.W. (2010). Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J. Exp. Med. 207, 339-344.
45. Group B.D.W. (2001). Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 69, 89-95.
46. Grunwald I., Dillmann K., Roth C., Backens M. and Reith W. (2007). [Supratentorial tumors]. Radiologe 47, 471-485.
47. Gupta P., Han S.Y., Holgado-Madruga M., Mitra S.S., Li G., Nitta R.T. and Wong A.J. (2010). Development of an EGFRvIII specific recombinant antibody. BMC Biotechnol. 10, 72.
48. Hamaya K., Doi K., Tanaka T. and Nishimoto A. (1985). The determination of glial fibrillary acidic protein for the diagnosis and histogenetic study of central nervous system tumors: a study of 152 cases. Acta Med. Okayama 39, 453-462.
49. Hartmann C. and von Deimling A. (2009). Molecular pathology of oligodendroglial tumors. Recent Results Cancer Res. 171, 25-49.
50. Hartmann C., Johnk L., Kitange G., Wu Y., Ashworth L.K., Jenkins R.B. and Louis D.N. (2002). Transcript map of the 3.7-Mb D19S112-D19S246 candidate tumor suppressor region on the long arm of chromosome 19. Cancer Res. 62, 4100-4108.
51. Hartmann C., Meyer J., Balss J., Capper D., Mueller W., Christians A., Felsberg J., Wolter M., Mawrin C., Wick W., Weller M., Herold-Mende C., Unterberg A., Jeuken J.W., Wesseling P., Reifenberger G. and von Deimling A. (2009). Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol. 118, 469-474.
52. Hartmann C., Hentschel B., Wick W., Capper D., Felsberg J., Simon M., Westphal M., Schackert G., Meyermann R., Pietsch T., Reifenberger G., Weller M., Loeffler M. and von Deimling A. (2010). Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol. 120, 707-718.
53. He J., Mokhtari K., Sanson M., Marie Y., Kujas M., Huguet S., Leuraud P., Capelle L., Delattre J.Y., Poirier J. and Hoang-Xuan K. (2001). Glioblastomas with an oligodendroglial component: a pathological and molecular study. J. Neuropathol. Exp. Neurol. 60, 863-871.
54. Hegi M.E., Diserens A.C., Godard S., Dietrich P.Y., Regli L., Ostermann S., Otten P., Van Melle G., de Tribolet N. and Stupp R. (2004). Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin. Cancer Res. 10, 1871-1874.
55. Hegi M.E., Diserens A.C., Gorlia T., Hamou M.F., de Tribolet N., Weller M., Kros J.M., Hainfellner J.A., Mason W., Mariani L., Bromberg J.E., Hau P., Mirimanoff R.O., Cairncross J.G., Janzer R.C. and Stupp R. (2005). MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 352, 997-1003.
56. Herbert J., Wilcox J.N., Pham K.T., Fremeau R.T. Jr, Zeviani M., Dwork A., Soprano D.R., Makover A., Goodman D.S. and Zimmerman E.A. (1986). Transthyretin: a choroid plexus-specific transport protein in human brain. The 1986 S. Weir Mitchell award. Neurology. 36, 900-911.
57. Herrlinger U., Rieger J., Koch D., Loeser S., Blaschke B., Kortmann R.D., Steinbach J.P., Hundsberger T., Wick W., Meyermann R., Tan T.C., Sommer C., Bamberg M., Reifenberger G. and Weller M. (2006). Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03. J. Clin. Oncol. 24, 4412-4417.
58. Herrmann M. and Ehrenreich H. (2003). Brain derived proteins as markers of acute stroke: their relation to pathophysiology, outcome prediction and neuroprotective drug monitoring. Restor. Neurol. Neurosci. 21, 177-190.
59. Hills D., Rowlinson-Busza G. and Gullick W.J. (1995). Specific targeting of a mutant, activated FGF receptor found in glioblastoma using a monoclonal antibody. Int. J. Cancer. 63, 537-543.
60. Homma T., Fukushima T., Vaccarella S., Yonekawa Y., Di Patre P.L., Franceschi S. and Ohgaki H. (2006). Correlation among pathology, genotype, and patient outcomes in glioblastoma. J. Neuropathol. Exp. Neurol. 65, 846-854.
61. Houillier C., Lejeune J., Benouaich-Amiel A., Laigle-Donadey F., Criniere E., Mokhtari K., Thillet J., Delattre J.Y., Hoang-Xuan K. and Sanson M. (2006). Prognostic impact of molecular markers in a series of 220 primary glioblastomas. Cancer 106, 2218-2223.
62. Huber P.A. (1997). Caldesmon. Int. J. Biochem. Cell Biol. 29, 1047-1051.
63. Humphrey P.A., Wong A.J., Vogelstein B., Zalutsky M.R., Fuller G.N., Archer G.E., Friedman H.S., Kwatra M.M., Bigner S.H. and Bigner D.D. (1990). Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma. Proc. Natl. Acad. Sci. USA 87, 4207-4211.
64. Huttner H.B., Janich P., Kohrmann M., Jaszai J., Siebzehnrubl F., Blumcke I., Suttorp M., Gahr M., Kuhnt D., Nimsky C., Krex D., Schackert G., Lowenbruck K., Reichmann H., Juttler E., Hacke W., Schellinger P.D., Schwab S., Wilsch-Brauninger M., Marzesco A.M. and Corbeil D. (2008). The stem cell marker prominin-1/CD133 on membrane particles in human cerebrospinal fluid offers novel approaches for studying central nervous system disease. Stem Cells 26, 698-705.
65. Ichimura K., Vogazianou A.P., Liu L., Pearson D.M., Backlund L.M., Plant K., Baird K., Langford C.F., Gregory S.G. and Collins V.P. (2007). 1p36 is a preferential target of chromosome 1 deletions in astrocytic tumours and homozygously deleted in a subset of glioblastomas. Oncogene 27, 2097-2108.
66. Ichimura K., Pearson D.M., Kocialkowski S., Backlund L.M., Chan R., Jones D.T. and Collins V.P. (2009). IDH1 mutations are present in the majority of common adult gliomas but are rare in primary glioblastomas. Neuro Oncol. 11, 1-7.
67. Idbaih A., Marie Y., Pierron G., Brennetot C., Hoang-Xuan K., Kujas M., Mokhtari K., Sanson M., Lejeune J., Aurias A., Delattre O. and Delattre J.Y. (2005). Two types of chromosome 1p losses with opposite significance in gliomas. Ann. Neurol. 58, 483-487.
68. Jacque C.M., Vinner C., Kujas M., Raoul M., Racadot J. and Baumann N.A. (1978). Determination of glial fibrillary acidic protein (GFAP) in human brain tumors. J. Neurol. Sci. 35, 147-155.
69. Jaeckle K.A., Eyre H.J., Townsend J.J., Schulman S., Knudson H.M., Belanich M., Yarosh D.B., Bearman S.I., Giroux D.J. and Schold S.C. (1998). Correlation of tumor O6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: a Southwest Oncology Group study. J. Clin. Oncol. 16, 3310-3315.
70. Jenkins R.B., Blair H., Ballman K.V., Giannini C., Arusell R.M., Law M., Flynn H., Passe S., Felten S., Brown P.D., Shaw E.G. and Buckner J.C. (2006). A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res. 66, 9852-9861.
71. Jin G., Reitman Z.J., Spasojevic I., Batinic-Haberle I., Yang J., Schmidt-Kittler O., Bigner D.D. and Yan H. (2011). 2-Hydroxyglutarate Production, but Not Dominant Negative Function, Is Conferred by Glioma-Derived NADP-Dependent Isocitrate Dehydrogenase Mutations. PLoS One. 6, e16812.
72. Jung C.S., Foerch C., Schanzer A., Heck A., Plate K.H., Seifert V., Steinmetz H., Raabe A. and Sitzer M. (2007). Serum GFAP is a diagnostic marker for glioblastoma multiforme. Brain 130, 3336-3341.
73. Jungbluth A.A., Stockert E., Huang H.J., Collins V.P., Coplan K., Iversen K., Kolb D., Johns T.J., Scott A.M., Gullick W.J., Ritter G., Cohen L., Scanlan M.J., Cavenee W.K. and Old L.J. (2003). A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor. Proc. Natl. Acad. Sci. USA 100, 639-644.
74. Kaneko M.K., Tian W., Takano S., Suzuki H., Sawa Y., Hozumi Y., Goto K., Yamazaki K., Kitanaka C. and Kato Y. (2011). Establishment of a novel monoclonal antibody SMab-1 specific for IDH1-R132S mutation. Biochem Biophys Res Commun. 25, 608-613
75. Kang M.R., Kim M.S., Oh J.E., Kim Y.R., Song S.Y., Seo S.I., Lee J.Y., Yoo N.J. and Lee S.H. (2009). Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers. Int. J. Cancer 125, 353-355.
76. Kato Y., Jin G., Kuan C.T., McLendon R.E., Yan H. and Bigner D.D. (2009). A monoclonal antibody IMab-1 specifically recognizes IDH1R132H, the most common glioma-derived mutation. Biochem. Biophys. Res. Commun. 390, 547-551.
77. Khwaja F.W., Nolen J.D., Mendrinos S.E., Lewis M.M., Olson J.J., Pohl J., Van Meir E.G., Ritchie J.C. and Brat D.J. (2006). Proteomic analysis of cerebrospinal fluid discriminates malignant and nonmalignant disease of the central nervous system and identifies specific protein markers. Proteomics 6, 6277-6287.
78. Kim T.S., Halliday A.L., Hedley-Whyte E.T. and Convery K. (1991). Correlates of survival and the Daumas-Duport grading system for astrocytomas. J. Neurosurg. 74, 27-37.
79. Kleihues P. and Ohgaki H. (1999). Primary and secondary glioblastomas: from concept to clinical diagnosis. Neuro Oncol. 1, 44-51.
80. Kleihues P., Burger P.C., Scheithauer B.W. and Zülch K.J. (1993). Histological typing of tumours of the central nervous system. Springer-Verlag. Berlin, Heidelberg, New York.
81. Kleihues P., Burger P.C. and Collins V.P. (2000). Glioblastoma. IARC Press. Lyon.
82. Kraus J.A., Lamszus K., Glesmann N., Beck M., Wolter M., Sabel M., Krex D., Klockgether T., Reifenberger G. and Schlegel U. (2001). Molecular genetic alterations in glioblastomas with oligodendroglial component. Acta Neuropathol. 101, 311-320.
83. Krex D., Klink B., Hartmann C., von Deimling A., Pietsch T., Simon M., Sabel M., Steinbach J.P., Heese O., Reifenberger G., Weller M. and Schackert G. (2007). Long-term survival with glioblastoma multiforme. Brain 130, 2596-2606.
84. Lavon I., Zrihan D., Zelikovitch B., Fellig Y., Fuchs D., Soffer D. and Siegal T. (2007). Longitudinal assessment of genetic and epigenetic markers in oligodendrogliomas. Clin. Cancer Res. 13, 1429-1437.
85. Levin N., Lavon I., Zelikovitsh B., Fuchs D., Bokstein F., Fellig Y. and Siegal T. (2006). Progressive low-grade oligodendrogliomas: response to temozolomide and correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression. Cancer 106, 1759-1765.
86. Lignelid H., Collins V.P. and Jacobsson B. (1997). Cystatin C and transthyretin expression in normal and neoplastic tissues of the human brain and pituitary. Acta Neuropathol. 93, 494-500.
87. Louis D.N. and International Agency for Research on Cancer (2007). WHO classification of tumours of the central nervous system. International Agency for Research on Cancer. Lyon.
88. Mardis E.R., Ding L., Dooling D.J., Larson D.E., McLellan M.D., Chen K., Koboldt D.C., Fulton R.S., Delehaunty K.D., McGrath S.D., Fulton L.A., Locke D.P., Magrini V.J., Abbott R.M., Vickery T.L., Reed J.S., Robinson J.S., Wylie T., Smith S.M., Carmichael L., Eldred J.M., Harris C.C., Walker J., Peck J.B., Du F., Dukes A.F., Sanderson G.E., Brummett A.M., Clark E., McMichael J.F., Meyer R.J., Schindler J.K., Pohl C.S., Wallis J.W., Shi X., Lin L., Schmidt H., Tang Y., Haipek C., Wiechert M.E., Ivy J.V., Kalicki J., Elliott G., Ries R.E., Payton J.E., Westervelt P., Tomasson M.H., Watson M.A., Baty J., Heath S., Shannon W.D., Nagarajan R., Link D.C., Walter M.J., Graubert T.A., DiPersio J.F., Wilson R.K. and Ley T.J. (2009). Recurring mutations found by sequencing an acute myeloid leukemia genome. N. Engl. J. Med. 361, 1058-1066.
89. Margetts J.C. and Kalyan-Raman U.P. (1989). Giant-celled glioblastoma of brain. A clinico-pathological and radiological study of ten cases (including immunohistochemistry and ultrastructure). Cancer 63, 524-531.
90. Mellinghoff I.K., Wang M.Y., Vivanco I., Haas-Kogan D.A., Zhu S., Dia E.Q., Lu K.V., Yoshimoto K., Huang J.H., Chute D.J., Riggs B.L., Horvath S., Liau L.M., Cavenee W.K., Rao P.N., Beroukhim R., Peck T.C., Lee J.C., Sellers W.R., Stokoe D., Prados M., Cloughesy T.F., Sawyers C.L. and Mischel P.S. (2005). Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N. Engl. J. Med. 353, 2012-2024.
91. Miller C.R., Dunham C.P., Scheithauer B.W. and Perry A. (2006). Significance of necrosis in grading of oligodendroglial neoplasms: a clinicopathologic and genetic study of newly diagnosed high-grade gliomas. J. Clin. Oncol. 24, 5419-5426.
92. Nakagawachi T., Soejima H., Urano T., Zhao W., Higashimoto K., Satoh Y., Matsukura S., Kudo S., Kitajima Y., Harada H., Furukawa K., Matsuzaki H., Emi M., Nakabeppu Y., Miyazaki K., Sekiguchi M. and Mukai T. (2003). Silencing effect of CpG island hypermethylation and histone modifications on O6-methylguanine-DNA methyltransferase (MGMT) gene expression in human cancer. Oncogene 22, 8835-8844.
93. Nelson J.S., Tsukada Y., Schoenfeld D., Fulling K., Lamarche J. and Peress N. (1983). Necrosis as a prognostic criterion in malignant supratentorial, astrocytic gliomas. Cancer 52, 550-554.
94. Nobusawa S., Watanabe T., Kleihues P. and Ohgaki H. (2009). IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin. Cancer Res. 15, 6002-6007.
95. Nutt C.L., Betensky R.A., Brower M.A., Batchelor T.T., Louis D.N. and Stemmer-Rachamimov A.O. (2005). YKL-40 is a differential diagnostic marker for histologic subtypes of high-grade gliomas. Clin. Cancer Res. 11, 2258-2264.
96. Ohgaki H., Dessen P., Jourde B., Horstmann S., Nishikawa T., Di Patre P.L., Burkhard C., Schuler D., Probst-Hensch N.M., Maiorka P.C., Baeza N., Pisani P., Yonekawa Y., Yasargil M.G., Lutolf U.M. and Kleihues P. (2004). Genetic pathways to glioblastoma: a populationbased study. Cancer Res. 64, 6892-6899.
97. Ohnishi M., Matsumoto T., Nagashio R., Kageyama T., Utsuki S., Oka H., Okayasu I. and Sato Y. (2009). Proteomics of tumor-specific proteins in cerebrospinal fluid of patients with astrocytoma: usefulness of gelsolin protein. Pathol. Int. 59, 797-803.
98. Okamoto S., Yoshikawa K., Obata Y., Shibuya M., Aoki S., Yoshida J. and Takahashi T. (1996). Monoclonal antibody against the fusion junction of a deletion-mutant epidermal growth factor receptor. Br. J. Cancer 73, 1366-1372.
99. Olsson M. and Lindahl T. (1980). Repair of alkylated DNA in Escherichia coli. Methyl group transfer from O6-methylguanine to a protein cysteine residue. J. Biol. Chem. 255, 10569-10571.
100. Omuro A.M., Faivre S. and Raymond E. (2007). Lessons learned in the development of targeted therapy for malignant gliomas. Mol. Cancer Ther. 6, 1909-1919.
101. Papadopoulos M.C., Saadoun S., Davies D.C. and Bell B.A. (2001). Emerging molecular mechanisms of brain tumour oedema. Br. J. Neurosurg. 15, 101-108.
102. Parsons D.W., Jones S., Zhang X., Lin J.C., Leary R.J., Angenendt P., Mankoo P., Carter H., Siu I.M., Gallia G.L., Olivi A., McLendon R., Rasheed B.A., Keir S., Nikolskaya T., Nikolsky Y., Busam D.A., Tekleab H., Diaz L.A., Jr., Hartigan J., Smith D.R., Strausberg R.L., Marie S.K., Shinjo S.M., Yan H., Riggins G.J., Bigner D.D., Karchin R., Papadopoulos N., Parmigiani G., Vogelstein B., Velculescu V.E. and Kinzler K.W. (2008). An integrated genomic analysis of human glioblastoma multiforme. Science 321, 1807-1812.
103. Pegg A.E., Wiest L., Foote R.S., Mitra S. and Perry W. (1983). Purification and properties of O6-methylguanine-DNA transmethylase from rat liver. J. Biol. Chem. 258, 2327-2333.
104. Peles E., Lidar Z., Simon A.J., Grossman R., Nass D. and Ram Z. (2004). Angiogenic factors in the cerebrospinal fluid of patients with astrocytic brain tumors. Neurosurgery. 55, 562-567.
105. Pelinka L.E., Kroepfl A., Schmidhammer R., Krenn M., Buchinger W., Redl H. and Raabe A. (2004). Glial fibrillary acidic protein in serum after traumatic brain injury and multiple trauma. J. Trauma. 57, 1006-1012.
106. Perry A., Aldape K.D., George D.H. and Burger P.C. (2004). Small cell astrocytoma: an aggressive variant that is clinicopathologically and genetically distinct from anaplastic oligodendroglioma. Cancer 101, 2318-2326.
107. Plate K.H. and Risau W. (1995). Angiogenesis in malignant gliomas. Glia 15, 339-347.
108. Prados M.D., Chang S.M., Butowski N., DeBoer R., Parvataneni R., Carliner H., Kabuubi P., Ayers-Ringler J., Rabbitt J., Page M., Fedoroff A., Sneed P.K., Berger M.S., McDermott M.W., Parsa A.T., Vandenberg S., James C.D., Lamborn K.R., Stokoe D. and Haas-Kogan D.A. (2009). Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. J. Clin. Oncol. 27, 579-584.
109. Preusser M., Charles Janzer R., Felsberg J., Reifenberger G., Hamou M.F., Diserens A.C., Stupp R., Gorlia T., Marosi C., Heinzl H., Hainfellner J.A. and Hegi M. (2008). Anti-O6-methylguaninemethyltransferase (MGMT) immunohistochemistry in glioblastoma multiforme: observer variability and lack of association with patient survival impede its use as clinical biomarker. Brain Pathol. 18, 520-532.
110. Reitman Z.J., Jin G., Karoly E.D., Spasojevic I., Yang J., Kinzler K.W., He Y., Bigner D.D., Vogelstein B. and Yan H. (2011). Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome. Proc. Natl. Acad. Sci. USA 22, 3270-3275.
111. Revesz T., Scaravilli F., Coutinho L., Cockburn H., Sacares P. and Thomas D.G. (1993). Reliability of histological diagnosis including grading in gliomas biopsied by image-guided stereotactic technique. Brain 116, 781-793.
112. Rittling S.R. and Denhardt D.T. (1999). Osteopontin function in pathology: lessons from osteopontin-deficient mice. Exp. Nephrol. 7, 103-113.
113. Rodriguez F.J., Thibodeau S.N., Jenkins R.B., Schowalter K.V., Caron B.L., O'Neill B P., James C.D., Passe S., Slezak J. and Giannini C. (2008). MGMT immunohistochemical expression and promoter methylation in human glioblastoma. Appl. Immunohistochem. Mol. Morphol. 16, 59-65.
114. Royds J.A., Ironside J.W., Taylor C.B., Graham D.I. and Timperley W.R. (1986). An immunohistochemical study of glial and neuronal markers in primary neoplasms of the central nervous system. Acta Neuropathol. 70, 320-326.
115. Sampath P., Weaver C.E., Sungarian A., Cortez S., Alderson L. and Stopa E.G. (2004). Cerebrospinal fluid (vascular endothelial growth factor) and serologic (recoverin) tumor markers for malignant glioma. Cancer Control. 11, 174-180.
116. Sanson M., Marie Y., Paris S., Idbaih A., Laffaire J., Ducray F., El Hallani S., Boisselier B., Mokhtari K., Hoang-Xuan K. and Delattre J.Y. (2009). Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J. Clin. Oncol. 27, 4150-4154.
117. Sawyers C.L. (2008). The cancer biomarker problem. Nature 452, 548-552.
118. Schneider S.W., Ludwig T., Tatenhorst L., Braune S., Oberleithner H., Senner V. and Paulus W. (2004). Glioblastoma cells release factors that disrupt blood-brain barrier features. Acta Neuropathol. (Berl). 107, 272-276.
119. Schuhmann M.U., Zucht H.D., Nassimi R., Heine G., Schneekloth C.G., Stuerenburg H.J. and Selle H. (2010). Peptide screening of cerebrospinal fluid in patients with glioblastoma multiforme. Eur. J. Surg. Oncol. 36, 201-207.
120. Sellner L., Capper D., Meyer J., Langhans C.D., Hartog C.M., Pfeifer H., Serve H., Ho A.D., Okun J.G., Kramer A. and Von Deimling A. (2010). Increased levels of 2-hydroxyglutarate in AML patients with IDH1-R132H and IDH2-R140Q mutations. Eur. J. Haematol. 85, 457-459.
121. Shinojima N., Kochi M., Hamada J., Nakamura H., Yano S., Makino K., Tsuiki H., Tada K., Kuratsu J., Ishimaru Y. and Ushio Y. (2004). The influence of sex and the presence of giant cells on postoperative long-term survival in adult patients with supratentorial glioblastoma multiforme. J. Neurosurg. 101, 219-226.
122. Shnaper S., Desbaillets I., Brown D.A., Murat A., Migliavacca E., Schluep M., Ostermann S., Hamou M.F., Stupp R., Breit S.N., de Tribolet N. and Hegi M.E. (2009). Elevated levels of MIC-1/ GDF15 in the cerebro-spinal fluid (CSF) of patients are associated with glioblastoma and worse outcome. Int. J. Cancer. 1, 2624-2630.
123. Stupp R. and Weber D.C. (2005). The role of radio- and chemotherapy in glioblastoma. Onkologie 28, 315-317.
124. Stupp R., Mason W.P., van den Bent M.J., Weller M., Fisher B., Taphoorn M.J., Belanger K., Brandes A.A., Marosi C., Bogdahn U., Curschmann J., Janzer R.C., Ludwin S.K., Gorlia T., Allgeier A., Lacombe D., Cairncross J.G., Eisenhauer E. and Mirimanoff R.O. (2005). Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352, 987-996.
125. Stupp R., Hegi M.E., Mason W.P., van den Bent M.J., Taphoorn M.J., Janzer R.C., Ludwin S.K., Allgeier A., Fisher B., Belanger K., Hau P., Brandes A.A., Gijtenbeek J., Marosi C., Vecht C.J., Mokhtari K., Wesseling P., Villa S., Eisenhauer E., Gorlia T., Weller M., Lacombe D., Cairncross J.G. and Mirimanoff R.O. (2009). Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomized phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 10, 459-466.
126. Takahashi J.A., Fukumoto M., Igarashi K., Oda Y., Kikuchi H. and Hatanaka M. (1992). Correlation of basic fibroblast growth factor expression levels with the degree of malignancy and vascularity in human gliomas. J. Neurosurg. 76, 792-798.
127. Takano S., Yoshii Y., Kondo S., Suzuki H., Maruno T., Shirai S. and Nose T. (1996). Concentration of vascular endothelial growth factor in the serum and tumor tissue of brain tumor patients. Cancer Res. 56, 2185-2190.
128. Tanwar M.K., Gilbert M.R. and Holland E.C. (2002). Gene expression microarray analysis reveals YKL-40 to be a potential serum marker for malignant character in human glioma. Cancer Res. 62, 4364-4368.
129. Taomoto K., Kokunai T., Okuda T., Tamaki N., Matsumoto S. and Hashimoto N. (1987). [The value of neuron specific enolase (NSE) in patients with brain tumors]. No To Shinkei 39, 169-173.
130. van den Bent M.J., Carpentier A.F., Brandes A.A., Sanson M., Taphoorn M.J., Bernsen H.J., Frenay M., Tijssen C.C., Grisold W., Sipos L., Haaxma-Reiche H., Kros J.M., van Kouwenhoven M.C., Vecht C.J., Allgeier A., Lacombe D. and Gorlia T. (2006). Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J. Clin. Oncol. 24, 2715-2722.
131. van den Bent M.J., Brandes A.A., Rampling R., Kouwenhoven M.C., Kros J.M., Carpentier A.F., Clement P.M., Frenay M., Campone M., Baurain J.F., Armand J.P., Taphoorn M.J., Tosoni A., Kletzl H., Klughammer B., Lacombe D. and Gorlia T. (2009a). Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. J. Clin. Oncol. 27, 1268-1274.
132. van den Bent M.J., Dubbink H.J., Sanson M., van der Lee-Haarloo C.R., Hegi M., Jeuken J.W., Ibdaih A., Brandes A.A., Taphoorn M.J., Frenay M., Lacombe D., Gorlia T., Dinjens W.N. and Kros J.M. (2009b). MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951. J. Clin. Oncol. 27, 5881-5886.
133. van der Flier M., Stockhammer G., Vonk G.J., Nikkels P.G., van Diemen-Steenvoorde R.A., van der Vlist G.J., Rupert S.W., Schmutzhard E., Gunsilius E., Gastl G., Hoepelman A.I., Kimpen J.L. and Geelen S.P. (2001). Vascular endothelial growth factor in bacterial meningitis: detection in cerebrospinal fluid and localization in postmortem brain. J. Infect. Dis. 183, 149-153.
134. von Deimling A., Korshunov A. and Hartmann C. (2011). The next generation of glioma biomarkers: MGMT methylation, BRAF fusions and IDH1 mutations. Brain Pathol. 21, 74-87.
135. Voorhies R.M., Sundaresan N. and Thaler H.T. (1980). The single supratentorial lesion. An evaluation of preoperative diagnostic tests. J. Neurosurg. 53, 364-368.
136. Weiler M., Hartmann C., Wiewrodt D., Herrlinger U., Gorlia T., Bahr O., Meyermann R., Bamberg M., Tatagiba M., von Deimling A., Weller M. and Wick W. (2010). Chemoradiotherapy of newly diagnosed glioblastoma with intensified temozolomide. Int. J. Radiat. Oncol. Biol. Phys. 77, 670-676.
137. Weller M., Felsberg J., Hartmann C., Berger H., Steinbach J.P., Schramm J., Westphal M., Schackert G., Simon M., Tonn J.C., Heese O., Krex D., Nikkhah G., Pietsch T., Wiestler O., Reifenberger G., von Deimling A. and Loeffler M. (2009). Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. J. Clin. Oncol. 27, 5743-5750.
138. Wick W., Stupp R., Beule A.C., Bromberg J., Wick A., Ernemann U., Platten M., Marosi C., Mason W.P., van den Bent M., Weller M., Rorden C., Karnath H.O., European Organisation for Research and Treatment of Cancer and the National Cancer Institute of Canada Clinical Trials Group. (2008). A novel tool to analyze MRI recurrence patterns in glioblastoma. Neuro. Oncol. 10, 1019-1024.
139. Wick W., Platten M. and Weller M. (2009). New (alternative) temozolomide regimens for the treatment of glioma. Neuro. Oncol. 11, 69-79.
140. Yan H., Parsons D.W., Jin G., McLendon R., Rasheed B.A., Yuan W., Kos I., Batinic-Haberle I., Jones S., Riggins G.J., Friedman H., Friedman A., Reardon D., Herndon J., Kinzler K.W., Velculescu V.E., Vogelstein B. and Bigner D.D. (2009). IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med. 19, 765-773.
141. Zawlik I., Vaccarella S., Kita D., Mittelbronn M., Franceschi S. and Ohgaki H. (2009). Promoter methylation and polymorphisms of the MGMT gene in glioblastomas: a population-based study. Neuroepidemiology 32, 21-29.
142. Zeppernick F., Ahmadi R., Campos B., Dictus C., Helmke B.M., Becker N., Lichter P., Unterberg A., Radlwimmer B. and Herold-Mende C.C. (2008). Stem cell marker CD133 affects clinical outcome in glioma patients. Clin. Cancer Res. 14, 123-129.
143. Zheng P.P., Hop W.C., Sillevis Smitt P.A., van den Bent M.J., Avezaat C.J., Luider T.M. and Kros J.M. (2005). Low-molecular weight caldesmon as a potential serum marker for glioma. Clin. Cancer Res. 11, 4388-4392.
144. Zheng P.P., Luider T.M., Pieters R., Avezaat C.J., van den Bent M.J., Sillevis Smitt P.A. and Kros J.M. (2003). Identification of tumorrelated proteins by proteomic analysis of cerebrospinal fluid from patients with primary brain tumors. J. Neuropathol. Exp. Neurol. 62, 855-862.
145. Zheng P.P., Sieuwerts A.M., Luider T.M., van der Weiden M., Sillevis-Smitt P.A. and Kros J.M. (2004). Differential expression of splicing variants of the human caldesmon gene (CALD1) in glioma neovascularization versus normal brain microvasculature. Am. J. Pathol. 164, 2217-2228.
146. Zougman A., Pilch B., Podtelejnikov A., Kiehntopf M., Schnabel C., Kumar C. and Mann M. (2008). Integrated analysis of the cerebrospinal fluid peptidome and proteome. J. Proteome Res. 7, 386-399.